Cancer Chemoprevention (e-bok)
Fler böcker inom
PDF med Adobe-kryptering
Om Adobe-kryptering
PDF-böcker lämpar sig inte för läsning på små skärmar, t ex mobiler.
Kan laddas ned under 24 månader, dock max 6 gånger.
Antal sidor
Humana Press
Hawk, Ernest T.
Strategies for Cancer Chemoprevention
Cancer Chemoprevention (e-bok)

Cancer Chemoprevention E-bok

Volume 2: Strategies for Cancer Chemoprevention

E-bok (PDF - DRM), Engelska, 2008-08-17
Läs i Adobe DRM-kompatibel e-boksläsare. Tips på appar
Finns även som
Visa alla 2 format & utgåvor
Despite significant advances in cancer treatment and measures of neoplastic progression, drug effect (or early detection, overall cancer incidence has increased, pharmacodynamic markers), and markers that measure cancer-associated morbidity is considerable, and overall prognosis as well as predict responses to specific therapy. cancer survival has remained relatively flat over the past All these biomarkers have the potential to greatly augment several decades (1,2). However, new technology the development of successful chemoprevention therapies, allowing exploration of signal transduction pathways, but two specific types of biomarkers will have the most identification of cancer-associated genes, and imaging of immediate impact on successful chemopreventive drug tissue architecture and molecular and cellular function is development-those that measure the risk of developing increasing our understanding of carcinogenesis and cancer invasive life-threatening disease, and those whose mo- progression. This knowledge is moving the focus of cancer lation can "e;reasonably predict"e; clinical benefit and, therapeutics, including cancer preventive treatments, to therefore, serve as surrogate endpoints for later-occurring drugs that take advantage of cellular control mechanisms clinical disease. Thus far, the biomarker that best measures to selectively suppress cancer progression. these two phenomena is intraepithelial neoplasia (IEN) Carcinogenesis is now visualized as a multifocal, because it is a near obligate precursor to cancer.
Visa hela texten


Har du läst boken? Sätt ditt betyg »


Part I. Chemopreventive Agent Development Science; Characterization of Chemopreventive Agents in Natural Products; John M. Pezzuto, Jerome W. Kosmeder, II, Eun Jung Park, Sang Kook Lee, Muriel Cuendet, Joell Gills, Krishna Bhat, Simonida Grubjesic, Hye-Sung Park, Eugenia Mata-Greenwood, YingMeei Tan, Rong Yu, Daniel D. Lantvit, and A. Douglas Kinghorn; Preclinical Animal Models for the Development of Cancer Chemoprevention Drugs; Vernon E. Steele, Ronald A. Lubet, and Richard C. Moon; Potential Use of Transgenic Mice in Chemoprevention Studies; Ronald A. Lubet, Jeffrey Green, Vernon Steele, and Ming You; Modeling Human Colorectal Cancer in Mice for Chemoprevention Studies; Martin Lipkin and Sergio A. Lamprecht; Pathology of Incipient Neoplasia; Donald Earl Henson and Jorge Albores-Saavedra; Quantitative Nuclear Grade: Clinical Applications of the Quantitative Measurement of Nuclear Structure Using Image Analysis; Robert W. Veltri, Alan W. Partin, and M. Craig Miller; Enabling Discovery through Online Cancer Genome Databases and Analytic Tools; Robert L. Strausberg and Gregory J. Riggins; Functional Genomics for the Identification of Surrogate Endpoint Biomarkers in Breast Cancer Chemoprevention; Melissa A. Troester and Charles M. Perou; Clinical Applications of Proteomics; Emanuel F. Petricoin and Lance A. Liotta; Bioinformatics and Whole Genome Technologies; Richard Simon; Models of Absolute Risk: Uses, Estimation, and Validation; Mitchell H. Gail; Genetic Polymorphisms and Risk Management for Cancer Chemoprevention; Sonia de Assis and Peter G. Shields; Design Issues in Prostate Cancer Chemoprevention Trials: Lessons from the Prostate Cancer Prevention Trial; Ian M. Thompson and Charles A. Coltman, Jr.; Recruitment Strategies for Cancer Prevention Trials; Paul P. Carbone, Karen Sielaff, Mary Hamielec, and Howard Bailey; Part II. Cancer Chemoprevention at Major Cancer Target Sites; Prostate; Prostate Cancer Prevention; William G. Nelson, Angelo M. de Marzo, and Scott M. Lippman; Use of PSA to Evaluate Rick and Progression of Prostate Cancer; Bulent Akduman, Abelardo Errejon, and E. David Crawford; Breast; Clinical Approaches to Discovery and Testing of New Breast Cancer Prevention Drugs; Carol J. Fabian, Bruce F. Kimler, Matthew S. Mayo, William E. Grizzle, Shahla Masood, and Giske Ursin; Ductal Lavage: Its Role in Breast Cancer Risk Assessment and Risk Reduction; Joyce O'Shaughnessy and Andrea Decensi; Counteracting Estrogen as Breast Cancer Prevention; Kathrin Strasser-Weippl and Paul E. Goss; Colorectal; Chemoprevention of Colorectal Cancer: Clinical Strategies; Monica M. Bertagnolli and Stanley R. Hamilton; Screening in Risk Evaluation and Prevention of Colorectal Cancer; Bernard Levin; Lung; Strategies in Lung Cancer Chemoprevention; Edward S. Kim, Faye M. Johnson, Waun Ki Hong, and Fadlo R. Khuri; Lung Cancer Chemoprevention: An Opportunity for Direct Drug Delivery; James L. Mulshine and Luigi M. De Luca; Bladder; Bladder Cancer: Clinical Strategies for Cancer Chemoprevention; H. Barton Grossman, Anita L. Sabichi, and Yu Shen; Esophagus; Barrett's Esophagus: Strategies for Cancer Prevention; Brian J. Reid; Endoscopic Detection of Esophageal Neoplasia; Brian C. Jacobson and Jacques Van Dam